Genetically engineered mouse models (GEMMs) can support research on tumor initiation, progression, metastasis and immune interactions. The genetic background and tumor phenotype are considered for the selected model. MuriPhys can connect transgenic-colony management, imaging, physiological monitoring and study execution around the research question.
Below is a list of available models commonly used by MuriPhys researchers:
- Mice engineered to develop spontaneous tumors that metastasize naturally.
- Oncogene activation, such as KRAS or MYC, and tumor-suppressor alterations, such as p53 or PTEN, can drive tumor development. Metastatic behavior depends on the specific model.
- Examples:
- MMTV-PyMT (breast cancer, C57BL/6 mouse) → Lung metastases.
- KPC model (pancreatic cancer, KRAS^G12D/p53^R172H, C57BL/6) → Liver, lung metastases.
Advanced Drug Administration & Serial Injections
We specialize in the following routes of administration:
Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Intrathecal (IT), Intra Peritoneal (IP), Oral Gavage (PO), Topical, Slow-infusion and Continuous Infusions – supporting accurate systemic or localized therapeutic exposure.
Serial Injections – Enabling longitudinal drug administration studies to monitor treatment effects over time.
Quality Control: Mycoplasma Testing
Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.
At MuriPhys, we are dedicated to accelerating oncology drug discovery with specialized preclinical solutions. Contact us today to discuss how we can support your oncology research!
Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.